HENRY SCHEIN INC.

ISIN: US8064071025 WKN: 806407102 Asset Class: Stock



Company Profile

Henry Schein, Inc. engages in the provision of health care products and services to medical, dental, and veterinary office-based practitioners. It operates through the Healthcare Distribution and Technology and Value-Added Services segments. The Healthcare Distribution segment includes consumable products, laboratory, small and large equipment repair services, branded and generic pharmaceuticals, vaccines, surgical, diagnostic tests, infection-control products, and vitamins. The Technology and Value-Added Services segment offers financial on a non-recourse basis, network, and hardware services. The company was founded by Henry Schein and Esther Schein in 1932 and is headquartered in Melville, NY.

Financial figures, Fiscal year: from 31.12. to 30.12.

	20	23	20	22	202	21
Financial figures					Assets Liabilities and equity	
Current assets	4,488,000,000		3,988,000,000		3,844,035,000	
Common stock capital		1,000,000		1,000,000		1,371,000
Fixed assets	6,085,000,000		4,619,000,000		4,637,056,000	
Equity capital of a company		5,153,000,000		4,671,000,000		4,676,504,000
Cash and cash equivalents	171,000,000		117,000,000		117,965,000	
Accrued liabilities		0		0		0
Other assets	-		-		-	
Current liabilities		2,683,000,000		2,224,000,000		2,306,514,000
Prepayments and accrued income	-		-		-	
Non-current liabilities		2,737,000,000		1,712,000,000		1,498,073,000
Different income		-		-		-
Other liabilities		436,000,000		361,000,000		376,672,000
Total assets	10,573,000,000	10,573,000,000	8,607,000,000	8,607,000,000	8,481,091,000	8,481,091,000

Balance notes

	2023	2022	2021
Accounting standard	US-GAAP	US-GAAP	US-GAAP
Employees	25,000	22,000	21,600
Equity ratio	62.91%	68.50%	69.90%
Debt-equity ratio	58.97%	45.98%	43.07%

Others

	2023	2022	2021
Tax Expense Rate	22.14%	23.58%	23.76%

HENRY SCHEIN INC.

ISIN: US8064071025 WKN: 806407102 Asset Class: Stock

Income statement			
	2023	2022	2021
Turnover	12,339,000,000	12,647,000,000	12,401,021,000
Net income	416,000,000	538,000,000	623,914,000
EBIT	555,818,400	679,333,600	773,511,215
Operating income before taxes	542,000,000	721,000,000	830,548,000
Cash Flow	500,000,000	602,000,000	709,580,000
Net interest income	-70,000,000	-27,000,000	-21,149,000
Research and development expenses	-	-	-
Income taxes	120,000,000	170,000,000	197,349,000
Result from investments in subsidaries, associates and other	14,000,000	15,000,000	20,009,000
Revenues per employee	448,251	522,091	521,417

Board of Directors

Members of Management Board		
Bradley Sheares	Member of Board of Directors	
Reed Tuckson	Member of Board of Directors	
Anne Margulies	Member of Board of Directors	
Carol Raphael	Member of Board of Directors	
Carole Faig	Member of Board of Directors	
Deborah Derby	Member of Board of Directors	
Joseph Herring	Member of Board of Directors	
Kurt Kuehn	Member of Board of Directors	
Mark Mlotek	Member of Board of Directors	
Mohamad Ali	Member of Board of Directors	
Philip Laskaway	Member of Board of Directors	
Scott Serota	Member of Board of Directors	
Stanley M. Bergman	Chairman of Managing Board	
Brad Connett	Member of Executive Committee	
Christopher Pendergast	Member of Executive Committee	
David Brous	Member of Executive Committee	
James Mullins	Member of Executive Committee	
James P. Breslawski	Member of Executive Committee	
Leigh Benowitz	Member of Executive Committee	
Lorelei McGlynn	Member of Executive Committee	
Mark E. Mlotek	Member of Executive Committee	
Michael S. Ettinger	Member of Executive Committee	
René Willi	Member of Executive Committee	
Ronald N. South	Member of Executive Committee	
Trinh Clark	Member of Executive Committee	